Positive interim results from Nuedexta Phase 4 trial

Interim results from Avanir Pharmaceuticals' (NASDAQ:AVNR) 450-patient 12-week Phase 4 clinical trial of Nuedexta (dextromethorphan hydrobromide/quinidine sulfate) demonstrate a substantial reduction in symptoms of pseudobulbar effect (PBA) in patients with Alzheimer's disease. PBA is a neurologic condition characterized by sudden and uncontrolled outbursts of laughing and/or crying in patients with neurolgic disease/injury.

At baseline, patients had a mean CNS-LS score of 20.2 and suffered a median of 29 PBA episodes per week. At the end of the study, mean CNS-LS improved to 12.8 and median PBA episodes dropped to 5 per week.

77.8% of patients or caregivers rated themselves/patients as being much/very improved.

79.3% of clinicians rated the patient much/very much improved.

Nuedexta is the only FDA-approved treatment for PBA.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs